A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2019
At a glance
- Drugs Trabectedin (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 The study has been completed in Poland.
- 16 Feb 2018 Planned End Date changed from 18 Jan 2018 to 31 Dec 2018.